400 related articles for article (PubMed ID: 27409838)
1. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
2. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
4. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
[TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
7. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
[TBL] [Abstract][Full Text] [Related]
8. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
[TBL] [Abstract][Full Text] [Related]
10. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.
Mori A; Masuda K; Ohtsuka H; Shijo M; Ariake K; Fukase K; Sakata N; Mizuma M; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Fujishima F; Unno M
Cancer Sci; 2018 Dec; 109(12):3883-3895. PubMed ID: 30302867
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
12. E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Chong Z; Bao C; He J; Chen T; Zhong L; Li G; Li H; Fang L; Song Y; Fu G; Yang X; Lai L; Liu Y; Wang Q
Cell Mol Immunol; 2018 Dec; 15(12):1057-1070. PubMed ID: 30275535
[TBL] [Abstract][Full Text] [Related]
13. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
15. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
16. Recent insight into the role of FBXW7 as a tumor suppressor.
Yumimoto K; Nakayama KI
Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
[TBL] [Abstract][Full Text] [Related]
17. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
[TBL] [Abstract][Full Text] [Related]
18. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
[TBL] [Abstract][Full Text] [Related]
19. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
Zhao J; Wang Y; Mu C; Xu Y; Sang J
Oncogene; 2017 Aug; 36(35):5023-5034. PubMed ID: 28459460
[TBL] [Abstract][Full Text] [Related]
20. Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer.
Fang L; Yang Z; Zhou J; Tung JY; Hsiao CD; Wang L; Deng Y; Wang P; Wang J; Lee MH
Mol Cancer Ther; 2015 Jun; 14(6):1476-87. PubMed ID: 25855785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
